NAVB - Navidea Biopharm GAAP EPS of -$0.25 revenue of $0.08M November, 14 2022 08:47 AM Navidea Biopharmaceuticals Inc. Navidea Biopharm press release ( NYSE: NAVB ): Q3 GAAP EPS of -$0.25. Revenue of $0.08M (-91.8% Y/Y). Navidea ended the third quarter of 2022 with $4.6 million in cash and cash equivalents. Shares +1.92% PM. For further details see: Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M